Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep
Epilepsy & Behavior · 2026
DOI: 10.1016/j.yebeh.2025.110866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026. Verfasst von Andy Cheuk-Him Ng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgar…. Hauptthemen laut MEDLINE: Ethosuximide, Anticonvulsants, Epilepsy, Sleep. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Children's Hospital Research Institute, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Developmental and epileptic encephalopathy with spike-wave activation in sleep (D)EE-SWAS is characterized by a marked increase in epileptiform activity during non-REM sleep. This increase in sleep-related epileptic activity disturbs normal sleep architecture and leads to a stagnation and regression in various behavior and neurocognitive domains. Ethosuximide (ETX) targets T-type calcium channel in the thalamus, an area involved in the generation of sleep potentials and sleep-activated spikes, and as such, ETX had been tried in the past for (D)EE-SWAS. In this retrospective study, we reviewed our database for patients with (D)EE-SWAS-spectrum disorders treated with ETX. Among patients treated with ETX as an add-on therapy, 43.5% (10/23) achieved an absolute decrease in spike-wave index (SWI%) of 25 or more (ETX responder) at the first follow-up EEG compared to baseline; whereas 57.1% (12/21) were ETX responders at the second follow-up EEG. Statistical testing showed that ETX responder status was significantly associated with several clinical factors, including underlying etiology, focal interictal epileptiform discharges, and epilepsy syndrome. A trend towards an association of ETX responder and normal MRI was seen but did not reach statistical significance. Overall, our data supports the use of ETX in (D)EE-SWAS, and that it is possible to predict ETX responders based on clinical factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Neurosciences, Cum…
- Department of Community Health Sciences, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Förderung
- Alberta Children's Hospital Research Institute
- Canadian Institutes of Health Research
Zitieren
APA
Ng, A. C., Warriyar K V, V., D'Alfonso, S., & Scantlebury, M. H. (2026). Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110866
Vancouver
Ng AC, Warriyar K V V, D'Alfonso S, Scantlebury MH. Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep. Epilepsy & Behavior. 2026. doi:10.1016/j.yebeh.2025.110866
BibTeX
@article{Ng2026,
author = {Ng, Andy Cheuk-Him and Warriyar K V, Vineetha and D'Alfonso, Sabrina and Scantlebury, Morris H},
title = {Clinical features associated with a response to ethosuximide in developmental and epileptic encephalopathy with spike wave activation in sleep},
journal = {Epilepsy & Behavior},
year = {2026},
doi = {10.1016/j.yebeh.2025.110866}
}
EUVIMED